Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8...
Read MoreMar 14, 2024
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8...
Read MoreOct 23, 2023
FRIDAY, Oct. 20, 2023 (HealthDay News) — There is a clear, unmet need for tolerable...
Read MoreAug 7, 2023
The unbalanced translocation der (1;7)(q10;p10) is a characteristic cytogenetic abnormality...
Read MoreJun 15, 2023
The following is a summary of “Real-World Validation of Molecular International Prognostic...
Read MoreJun 12, 2023
Myelodysplastic syndromes (MDS) refer to a set of clonal hematopoietic disorders with fusion...
Read MoreMay 25, 2023
The following is a summary of “Clinical outcomes and characteristics of patients with...
Read MoreMar 13, 2023
To explore the clinical outcomes and characteristics of -mutated primary myelodysplastic syndromes...
Read MoreJan 23, 2023
MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life...
Read MoreJan 20, 2023
THURSDAY, Jan. 19, 2023 (HealthDay News) — Clinical characteristics, outcomes, and genetic...
Read MoreJan 16, 2023
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by UBA1 somatic mutations and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities such as cytopenia,...
Read MoreDec 12, 2022
The study aimed to evaluate pre-allogeneic hematopoietic stem cell transplantation (allo-HSCT) treatment, compare the endpoints related to disease management between pre-HSCT cytoreduction patients and upfront transplantation...
Read MoreNov 23, 2022
WEDNESDAY, Nov. 23, 2022 (HealthDay News) — About 40 percent of patients with lower-risk...
Read MoreOct 20, 2022
Thrombocytopenia is made worse when myelodysplastic syndromes with high risk are treated with...
Read MoreSep 12, 2022
Even after an allogeneic hematopoietic stem cell transplant (HCT), outcomes in TP53-mutant (mTP53)...
Read MoreSep 2, 2022
On July 7, 2020, the Food and Drug Administration authorized Inqovi (Otsuka Pharmaceutical Co.),...
Read MoreApr 22, 2022
The presence of significant variability within mutant TP53 acute myeloid leukemia (AML) and...
Read MoreJul 5, 2021
The value of pre-transplant cytoreductive therapy for patients with myelodysplastic syndromes...
Read MoreJun 24, 2021
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell diseases...
Read MoreJun 14, 2021
Bone marrow of patients with aplastic anemia (AA) is different from that of patients with myelodysplastic syndrome (MDS) and is difficult to identify by blood examination. IDEAL-IQ (iterative decomposition of water and fat with...
Read MoreJun 10, 2021
Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for...
Read MoreSed vitae nulla id ipsum molestie scelerisque vitae vitae ligula. Fusce a massa tortor.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.